Novartis-backed Gamida hits goal in phase 3 cancer trial

A phase 3 trial of Gamida Cell’s omidubicel in blood cancer patients has met its primary endpoint, sending the biotech’s stock up as much as 86% in premarket trading. The study found Gamida’s cells cut the time to neutrophil engraftment, suggesting the drug has benefits over umbilical cord blood.